Get the Stockscreener App
16.82
0.06%
0.01
After Hours:
16.72
-0.10
-0.59%
Bausch Lomb Corp stock is traded at $16.82, with a volume of 234.39K.
It is up +0.06% in the last 24 hours and up +6.93% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$16.81
Open:
$17
24h Volume:
234.39K
Relative Volume:
0.48
Market Cap:
$5.96B
Revenue:
$4.89B
Net Income/Loss:
$-263.00M
P/E Ratio:
-21.75
EPS:
-0.7734
Net Cash Flow:
$-167.84M
1W Performance:
+3.89%
1M Performance:
+6.93%
6M Performance:
+44.88%
1Y Performance:
-15.52%
1-Day Range:
$16.81
$17.34
1-Week Range:
$16.03
$17.70
52-Week Range:
$10.45
$20.71
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
16.82 | 5.95B | 4.89B | -263.00M | -167.84M | -0.7734 |
|
ISRG
Intuitive Surgical Inc
|
575.34 | 201.58B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
193.96 | 55.30B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.73 | 38.80B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
256.55 | 36.71B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
WST
West Pharmaceutical Services Inc
|
280.23 | 20.27B | 2.96B | 487.70M | 344.00M | 6.6758 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Neutral |
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
(BLCO) Daily Stock Insights (BLCO:CA) - news.stocktradersdaily.com
Oaktree Capital Management LP Makes New Investment in Bausch + Lomb Corporation $BLCO - MarketBeat
Will Bausch + Lomb Corporation (S2L) stock see valuation expansionWeekly Stock Report & Risk Managed Investment Strategies - Newser
Is Bausch + Lomb Corporation (S2L) stock a defensive play amid uncertainty2025 EndofYear Setup & Trade Opportunity Analysis Reports - Newser
Is Bausch + Lomb Corporation (S2L) stock a fit for income portfoliosJuly 2025 Rallies & Low Drawdown Momentum Ideas - Newser
Wall Street Cautious on Bausch + Lomb Corporation (BLCO), Here's Why - Finviz
Wall Street Cautious on Bausch + Lomb Corporation (BLCO), Here’s Why - Insider Monkey
Will Bausch + Lomb Corporation stock gain from lower inflationJuly 2025 Summary & Stock Timing and Entry Methods - Newser
Needham Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating - 富途牛牛
Balanced Hold Rating on Bausch + Lomb Amid Strategic Updates and Long-term Uncertainties - TipRanks
Is Bausch + Lomb Corporation (S2L) stock suitable for passive index fundsPortfolio Performance Report & Accurate Buy Signal Alerts - Newser
Morgan Stanley Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
BLCO Stock Still 16% Below IPO — Is Silver Point’s $38.7 Million Bet a Turning Point? - AOL.com
Bausch + Lomb (NYSE:BLCO) Shares Gap UpTime to Buy? - MarketBeat
BLCO Stock Still 16% Below IPO — Is Silver Point’s $38.7 Million Bet a Turning Point? - The Motley Fool
River Road Asset Management LLC Lowers Stock Position in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb and Ripple Therapeutics partner to develop sustained-release implants - Eyes On Eyecare
9 Best Up and Coming Canadian Stocks to Buy - Insider Monkey
Morgan Stanley Upgrades Bausch + Lomb Corp.(BLCO.US) to Buy Rating, Raises Target Price to $21 - 富途牛牛
(BLCO) Strategic Equity Report (BLCO:CA) - news.stocktradersdaily.com
Bausch + Lomb Shares Rise After Morgan Stanley Upgrade - marketscreener.com
Why Bausch + Lomb (BLCO) Stock Is Up Today - Finviz
Bausch + Lomb upgraded at Morgan Stanley on pipeline - Seeking Alpha
Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equal Weight, Adjusts PT to CA$29.41 From CA$19.64 - marketscreener.com
What analyst consensus says on Bausch + Lomb Corporation stock2025 Historical Comparison & Reliable Price Breakout Signals - Newser
Can Bausch + Lomb Corporation (S2L) stock double in coming yearsTrade Analysis Report & Free Expert Approved Momentum Trade Ideas - Newser
Published on: 2025-12-02 01:18:08 - Newser
Bausch + Lomb (BLCO): Is the Current Valuation Overlooked After Recent Share Recovery? - Yahoo Finance
Handelsbanken Fonder AB Takes Position in Bausch + Lomb Corporation $BLCO - MarketBeat
(BLCO) Equity Trading Insights (BLCO:CA) - news.stocktradersdaily.com
BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances - MSN
Behavioral Patterns of BLCO and Institutional Flows - news.stocktradersdaily.com
(BLCO) Market Performance Analysis (BLCO:CA) - news.stocktradersdaily.com
Bausch + Lomb Corporation (NYSE:BLCO) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Bausch + Lomb Lifts Guidance After Beating Earnings Forecasts - Finimize
Long Term Trading Analysis for (BLCO) (BLCO:CA) - news.stocktradersdaily.com
Citigroup Downgrades Bausch + Lomb (BLCO) - MSN
How Bausch + Lomb Corporation (S2L) stock responds to bond market2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Is Bausch + Lomb Corporation stock a buy for dividend growthJuly 2025 Levels & Real-Time Chart Breakout Alerts - newser.com
Is Bausch + Lomb Corporation (S2L) stock worth buying before Fed actionMarket Movement Recap & Consistent Profit Trading Strategies - newser.com
How big funds are accumulating Bausch + Lomb Corporation (S2L) stockJuly 2025 Intraday Action & AI Enhanced Execution Alerts - newser.com
Trading (BLCO) With Integrated Risk Controls (BLCO:CA) - news.stocktradersdaily.com
Will Bausch + Lomb Corporation stock benefit from commodity supercycleJuly 2025 Big Picture & Real-Time Chart Breakout Alerts - newser.com
Will Bausch + Lomb Corporation stock announce special dividend2025 Fundamental Recap & AI Based Buy and Sell Signals - newser.com
Why global investors buy Bausch + Lomb Corporation stockEntry Point & Weekly Breakout Opportunity Watchlist - newser.com
Does Bausch + Lomb Corporation (S2L) stock trade below intrinsic valueWeekly Market Summary & Expert Approved Momentum Ideas - newser.com
Bausch + Lomb to Engage at Citi Global Healthcare Conference - The Globe and Mail
Real time breakdown of Bausch + Lomb Corporation stock performancePortfolio Risk Report & Weekly Consistent Profit Watchlists - newser.com
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.32%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):